What’s the research?
Metabolic dysfunction Associated Steatotic Diver Disease (MASLD) affects 1 in 4 women overall, and is twice as common in women after the menopause. This condition is linked with heart disease and liver cancer, and there are no licensed drug treatments for MASLD in the UK.
Hormone replacement therapy (HRT) affects the body’s metabolism, and may limit or prevent the development of MASLD after the menopause, but existing research is very scarce.
To find out more, we are designing research to study the metabolic effects of HRT and how it affects the liver. One of the research methods we are using is a clinical trial involving menopausal women.
What’s the opportunity for patients and the public?
We are looking for people with experience of menopause who have considered HRT. We want to hear your opinions on our research topic regardless of whether you have used HRT in the past.
Your opinions will inform the development of our research. We hope that findings from our research will improve our understanding of HRT and support people to make an informed decision when deciding on whether to use HRT.
Recent research has shown that the some effects of hormone replacement therapy can vary based on ethnicity. We are seeking input from people from all backgrounds, to ensure that our research addresses the needs and experiences of diverse and under-represented groups in research.
Your commitment would be one meeting up to 2 hours long, and will likely be in a group with other people. It may be either online or in-person depending on availability.
Reimbursement
You will be reimbursed for your time at £25 per hour of participation.
Organisation
Oxford Centre for Diabetes, Endocrinology & Metabolism
University of Oxford
Contact
For more information, contact Jiawen Dong: jiawen.dong@ocdem.ox.ac.uk